KVISTGAARD, Denmark - November 6, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2014 third quarter results on Thursday, November 13, 2014.
The management of Bavarian Nordic will host a conference call at 2:00 pm CET (8:00 am EST) on the same day to present the interim results followed by a Q&A session.
Dial-in numbers for the conference call are:
Denmark: +45 32 72 80 18
UK: +44 (0) 844 571 8957
USA: +1 866 682 8490
A live and archived webcast of the call and relevant slides will be available at http://bit.ly/1E8hgGt.
Contacts
U.S.: Seth Lewis, Vice President, Investor Relations. Phone: + 1 978-298-5654
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in Canada and in the European Union, where it is marketed under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com.